RE:RE:RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases In 2015 ONC came out with 8 news releases announcing orphan drug status approvals for 6 different indications and fda and EMA jurisdictions. The only one they have followed up on is the panc cancer at this time from what I can tell so the ODS has not made or had a lot of impact on the company to date so far.
One would think that with so many ods approvals that someone would step up and take the lead with the company.